BOLT News and Press, Bolt Biotherapeutics Inc.

2025-11-13 12:48:16 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics Read the full article on Seeking Alpha For...

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT)...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

2025-11-10 17:42:15 ET Bolt Biotherapeutics, Inc. (BOLT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.08%. The average open to low on the day of earnings was -2.93%. The average ope...

2025-11-10 17:37:14 ET Bolt Biotherapeutics, Inc. (BOLT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in BOLT stock price following earnings has averaged ±1.92% , with a median of 1.40...

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Ohio State University just unlocked why many cancer immunotherapies fail, identifying a protein stress pathway that can be blocked to restore immune cell fu...

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopha...

2025-08-14 17:05:18 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics Read the full article on Seeking Alpha For...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...